Chapter 1. Background: Trends in Cancer Diagnostics
1.1. Summary of Key Trends
1.2. Statistics Showing Impact of the Disease and the Need for Early Diagnosis
1.3. Prospects for Cancer Theranostics
Chapter 2. Developments in Cancer Imaging
2.1. Introduction
2.2. Virtual Colonoscopy (Application of Computed Tomography in Colon Cancer Screening)
Description and Status
Potential Impact
Competition
Outlook
2.3. Advances in Breast Cancer Imaging
Description and Status
Potential Impact
Competition
Outlook
2.4. Emerging Role of Positron Emission Tomography in Cancer Diagnostics
Description and Status
Potential Impact
Competition
Outlook
2.5. In Vivo Diagnostic Monoclonal Antibodies for Imaging Cancers
Description and Status
Potential Impact
Competition
Outlook
Chapter 3. Developments In Cancer In Vitro Diagnostics
3.1. Introduction
"Traditional Tumor" Markers
Technologies Used for Cancer In Vitro Diagnostics
Trends in Cancer In Vitro Diagnostics
3.2. Advances in In Vitro Colorectal Cancer Screening
Description and Status
Potential Impact
Competition
Outlook
3.3. Theranostic Applications of Cancer In Vitro Diagnostics: Erbitux and Epidermal Growth Factor Receptor
Description and Status
Potential Impact
Competition
Outlook
3.4. Theranostic Applications of Cancer In Vitro Diagnostics: Applications in Leukemia and Lymphoma Diagnostics
Description and Status
Potential Impact
Competition
Outlook
3.5. Changes in DNA Methylation: Application in Cancer Diagnostics
Description and Status
Potential Impact
Competition
Outlook
3.6. Selected Advances in the Search for Novel Cancer Biomarkers/Tests
Chapter 4. Business Outlook
4.1. Business Trends
Positron Emission Tomography
Breast Imaging: Mammography
In Vivo Diagnostic Monoclonal Antibodies
In Vitro Cancer Diagnostics
4.2. Company Profiles
Abbott Laboratories
Advanced Research Technologies
Applied Imaging
Cardinal Health
Celera Diagnostics
CTI Molecular Imaging
DakoCytomation
Epigenomics
Exact Sciences
GE Healthcare
Neoprobe
OncoMethylome Sciences
Philips Medical Systems
Roche Diagnostics
Siemens
Chapter 5. Expert Interviews
Roger Attick, CEO and President, CeMines, Inc.
David Bupp, President and CEO, Neoprobe
Gary Schweikhardt, President, Epigenomics, Inc.; Head of Diagnostics Strategic Business Unit, Epigenomics AG
L. Blair Shamel, Senior Vice President, Corporate Development, DiagnoCure
Daryl Sonnichsen, Pharm. D., Senior Director, Wyeth Clinical Pharmacology
References
Glossary
Index
List of Figures
Figure 2.1. Stages of Development of Colorectal Cancer
Figure 2.2. The Principle of Positron Emission Detectable by Tomography
List of Tables
Table 1.1. Incidence, Number of Deaths, and Relative 5-Year Survival Rates by Stage of Diagnosis for Selected Cancers (United States)
Table 1.2. American Cancer Society Recommendations for the Early Detection of Cancer in Average-Risk Asymptomatic People (2005)
Table 2.1. Multicenter Clinical Trials Comparing Computed Tomography Colonography with Colonoscopy
Table 2.2. Comparison of Computed Tomographic Colonography and Colonoscopy as Screening Tests for Colorectal Cancer and Polyps
Table 2.3. Summary of Breast Cancer Screening Techniques
Table 2.4. Selected Companies Marketing Imaging Systems for Detection and Diagnosis of Breast Cancer
Table 2.5. Positron Emission Tomography Cancer Imaging Applications Covered by Medicare
Table 2.6. Companies Developing/Marketing In Vivo Diagnostic, Monoclonal Antibody–Based Imaging Agents
Table 3.1. Selected In Vitro Diagnostic Assays Available or in Development for Colorectal Cancer Screening
Table 3.2. Selected Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies on the Market or in Development
Table 3.3. Selected Available Epidermal Growth Factor Receptor Tests/Reagents
Table 3.4. Selected Targeted Therapies on the Market for Treatment of Leukemia or Lymphoma
Table 3.5. Selected In Vitro Molecular Diagnostic Tests Available or in Development for Leukemia and Lymphoma
Table 3.6. Selected Examples of Diagnostic Company Activities to Search for Novel Cancer Biomarkers and Develop New Cancer Diagnostic Tests
